EnGene Reports Positive Preliminary Data for Bladder-Cancer Drug
By Nicholas G. Miller
EnGene Holdings reported positive preliminary data from an ongoing Phase 2 trial of its detalimogene voraplasmid drug to treat a form of bladder cancer.
Shares were up 65% to $9.93 in premarket trading.
The trial showed a complete response rate at six months of 62% and demonstrated a favorable tolerability profile, with 42% of patients experiencing a treatment-related adverse event, said EnGene on Tuesday.
The Saint-Laurent, Quebec-based company plans to submit a biologics license application in the second half of next year, with potential Food and Drug Administration approval in 2027, it said.
"Based on the emerging clinical profile and detalimogene's differentiated ease of use, we continue to believe there is a substantial commercial opportunity for detalimogene if approved," said EnGene Chief Executive Ron Cooper.
Write to Nicholas G. Miller at nicholas.miller@wsj.com.
(END) Dow Jones Newswires
November 11, 2025 08:13 ET (13:13 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Are TIPS ETFs the Best Way to Fight Inflation?
What’s Ahead for Stocks This Quarter—and Where to Invest
10 Best Blue-Chip Stocks to Buy for the Long Term
United States